Resources
9 Results (showing 1 - 9)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/21/2023 (updated 3/28/2024)
The Office of National Drug Control Policy (ONDCP) released a plan in response to fentanyl being adulterated or associated with xylazine, which was declared as an emerging drug threat in April 2023. Due to the effect of combining these substances, people may be less responsive to naloxone in an overdose situation. The response plan includes evidence-based prevention, treatment, and supply reduction action steps, goals, and performance measures.
Posted 11/7/2023 (updated 3/28/2024)
Grantees from the Implementation III & IV, Behavioral Health Support, Psychostimulant Support I & II cohorts are invited to this “re-welcome” webinar to kick-off the new project year.
Posted 10/31/2023 (updated 3/28/2024)
This webinar will welcome FY23 MAT Access II and re-welcome FY22 MAT-Access I recipients to the RCORP program, providing grantees an overview of the RCORP program, an introduction to HRSA’s Office of Federal Assistance Management, and information about the technical assistance and evaluation options for the award.
Posted 10/24/2023 (updated 3/28/2024)
Welcome Webinar FY23 Child and Adolescent Behavioral Health
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 12/13/2022 (updated 3/27/2024)
Posted 4/11/2023 (updated 3/27/2024)
The first phase of the campaign created by the White House Office of National Drug Control Policy (ONDCP) and Ad Council was launched to education young people on the dangers of fentanyl and the life-saving effects of Naloxone, a medicine that reverses opioid-related overdoses. This campaign expands on the Ad Council's The Real Deal on Fentanyl platform.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk